Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated March 19, 2019, is filed by Aurinia Pharmaceuticals Inc., a foreign private issuer. The filing incorporates by reference a news release (Exhibit 99.1) detailing the company's Fourth Quarter and Full Year 2018 financial results and operational highlights.
Key Financial Metrics
The provided text serves as a cover sheet and exhibit index. It does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the referenced Exhibit 99.1, which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. The existence of a news release regarding 2018 results implies a reporting of performance, but the specific variances are not disclosed in this document.
Guidance, Outlook, and Risks
Management commentary, future guidance, risk factors, and contingencies are not detailed in the provided text. The document confirms the filing is incorporated into the Registration Statement on Form F-10 (File No. 333-222413).
Investor Verification Checklist
- Verify the specific financial results for Q4 and Full Year 2018 by reviewing Exhibit 99.1 (News Release) referenced in this filing.
- Confirm the status of the Registration Statement on Form F-10 (File No. 333-222413) to which this report is incorporated.
- Review the full news release for operational highlights and any forward-looking statements not captured in this summary.